In the LOTUS trial, which evaluated the efficacy of the AKT inhibitor ipatasertib combined with paclitaxel in patients with metastatic triple-negative breast cancer, patients with PTEN-low tumors did not experience significant benefits, indicating potential resistance to AKT inhibition in the context of PTEN loss (78). The gene discussed is AKT1; the disease is triple-negative breast carcinoma.